

Hydrix Medical appoints Guardian sub-distributor in Malaysia to accelerate revenues

Hydrix Limited (ASX: **HYD**) (**Hydrix** or the **Company**) is pleased to announce that its wholly-owned subsidiary, Hydrix Medical Pty Ltd (**Hydrix Medical**) has entered into an exclusive sub-distribution agreement with **MK Trimedica Sdn Bhd** (**MK Trimedica** or the **Sub-distributor**), a leader for the past 25 years in the distribution of interventional cardiovascular products in Malaysia, to market and sell the Guardian, the world's only real-time implanted heart attack alert device.

Highlights

- Hydrix Medical grants exclusive rights to MK Trimedica to market and sell the Guardian in Malaysia
- Four-year initial term, which will automatically renew for two successive two year periods, unless terminated prior
- There are approximately 85,000 acute coronary syndrome events annually in Malaysia
- The Guardian is approved for marketing and distribution in Malaysia

Malaysia market opportunity for the Guardian

The Guardian from Avertix Medical, Inc. (formerly Angel Medical Systems, Inc.) is the world's first and only implanted real-time heart attack warning system. The device fills an unmet medical need by providing more effective diagnosis of a life-threatening condition compared to relying on patient symptoms alone for patients suffering from recurrent acute coronary syndrome events, including silent heart attacks.

Under the agreement, Hydrix Medical has appointed MK Trimedica to market and sell the Guardian, as sub-distributor, based on its 25 year track record successfully selling interventional cardiovascular products for global blue chip companies in Malaysia.

The initial sub-distribution term is four (4) years, which will automatically renew for two successive two year periods, unless Hydrix provides prior written notice of its decision not to renew, or the agreement is otherwise terminated in accordance with its terms. The sub-distribution agreement contains customary performance obligations and other terms and conditions.

Under the terms of its distribution agreement with Avertix, Hydrix Medical has the exclusive rights to distribute the Guardian in eight Asia Pacific countries, along with the right to appoint sub-distributors. The sub-distribution agreement with MK Trimedica represents the first of several sub-distributor appointments anticipated by Hydrix Medical. Hydrix expects that the appointment of sub-distributors to market and sell the Guardian will help accelerate revenues to Hydrix. In determining sub-distributor appointments, Hydrix Medical will seek to appoint third parties that have a strong track record selling cardiovascular products within their well-established cardiology and hospital networks.

The Guardian is approved for marketing and distribution in Malaysia. With a population of 33.5 million people, there is estimated to be more than 85,000 patients annually suffering from acute coronary syndrome events. Although Hydrix is not able to forecast revenue estimates from this agreement at this early stage, Hydrix anticipates the agreement will in due course be financially accretive.

Thomas Chin, MK Trimedec Executive Director & Founder commented:

"We are extremely pleased to partner with Hydrix Medical to accelerate their go to market plans for the Guardian in Malaysia. Our extensive knowledge and track record bringing interventional cardiovascular products to market gives us great confidence we can help patients at risk of recurrent acute coronary syndrome events with this disruptive device."

Vickie Edwards, Director Sales & Operations – Hydrix Medical commented:

"Hydrix Medical is very pleased to appoint MK Trimedec as sub-distribution partner for the Guardian. Their network credibility and local market knowledge within the extended cardiology community in Malaysia made their appointment a logical choice.

"This arrangement will help accelerate sales momentum for the Guardian and demonstrates the distribution reach that we can offer emerging medtech companies in S.E. Asia."

-ENDS-

Authorisation: This announcement has been authorised for release by the Board of Hydrix.

Contact Details: For more information, please contact:

Company Enquiries:

Gavin Coote
Executive Chairman

info@hydrix.com

+61 3 9550 8100

Legal Enquiries:

Alyn Tai
Partner, Holding Redlich

Alyn.Tai@holdingredlich.com

+61 3 9321 9834

Media Enquires:

Rod North
MD, Bourse Communications

rod@boursecommunications.com.au

+61 3 9510 8309

About Hydrix Limited

Hydrix Limited (ASX: HYD) is a powerful product innovation company. Hydrix's purpose is to enhance the health, safety, and well-being of a billion lives. The company leverages its powerful product innovation capability across three business segments: Services: design, engineer and deliver world first products and innovation; Ventures: invest in high potential MedTech clients; and Medical: distribute disruptive cardiovascular products.

For personal use only